By Mill Chart
Last update: Nov 8, 2024
EXELIXIS INC (NASDAQ:EXEL) is a hidden gem identified by our stock screening tool, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price. Let's dig deeper into the analysis.
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NASDAQ:EXEL has earned a 8 for valuation:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:EXEL has achieved a 8:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:EXEL, the assigned 8 reflects its health status:
ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:EXEL, the assigned 6 reflects its growth potential:
More Decent Value stocks can be found in our Decent Value screener.
For an up to date full fundamental analysis you can check the fundamental report of EXEL
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
44.06
-1.52 (-3.33%)
Find more stocks in the Stock Screener
EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and accelerating margins, EXEL presents a compelling case.
EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors.
EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.
EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.